WO2016125208A1 - アナツバメ巣を原材料とする素材、組成物及び素材の製造方法 - Google Patents
アナツバメ巣を原材料とする素材、組成物及び素材の製造方法 Download PDFInfo
- Publication number
- WO2016125208A1 WO2016125208A1 PCT/JP2015/003205 JP2015003205W WO2016125208A1 WO 2016125208 A1 WO2016125208 A1 WO 2016125208A1 JP 2015003205 W JP2015003205 W JP 2015003205W WO 2016125208 A1 WO2016125208 A1 WO 2016125208A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- yeast
- raw material
- nest
- genus
- swallow
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
Definitions
- the present invention relates to a raw material, a composition, and a method for producing the raw material that use swallow nests as raw materials.
- materials that have been produced from natural products that have been conventionally known do not exceed the range expected from the raw materials.
- unknown raw materials having functionality can be produced from raw materials by combining raw materials, a processing method of combined raw materials, or a purification method of processed raw materials.
- Patent Document 1 discloses a skin beautification promoter containing an enzyme degradation product of swallow nest as an active ingredient. Such a skin beautifying agent further contains a culture obtained by culturing yeast.
- the object of the present invention is to provide an unknown material that is expected to have functionality while using a natural product as a raw material.
- the material according to one embodiment of the present invention is a fermented yeast of bird's nest belonging to the genus Sphaeroides.
- the yeast fermented product is preferably used as any one of pharmaceuticals, quasi drugs, health supplement foods, nutritional supplement foods, processed foods and soft drinks.
- One embodiment of the present invention is a composition containing a fermented bird's nest yeast fermented product belonging to the genus Swanaceae. It is preferable that the composition is any one of pharmaceuticals, quasi drugs, foods for health supplements, foods for nutritional supplements, processed foods, and soft drinks.
- the composition is preferably a composition for improving allodynia or neuropathic pain.
- the composition is preferably a composition for at least one of prevention and improvement of lifestyle-related diseases.
- the lifestyle-related disease is preferably at least one of diabetes, hypertension, cardiac ischemic disease and cerebral ischemic disease.
- the composition is preferably a composition for preventing viral infection.
- One aspect of the present invention is a method for producing a raw material using a bird's nest belonging to the genus Swiftaceae.
- yeast is added to the raw material.
- the raw material is fermented with the yeast. It is preferable to add moisture to the raw material before fermentation. It is preferable to ferment the raw material together with the moisture. Fermentation is preferably performed in a sealed state. It is preferable to evaporate at least a part of the water after fermentation.
- One embodiment of the present invention includes diabetes, hypertension, cardiac ischemic disease, cerebral ischemic disease, viral infection, pathogenic microorganism infection, overwork and malnutrition, memory impairment, dry skin, formation of wrinkles associated with dry skin, allodynia And administration of a fermented bird's nest yeast fermentation product belonging to the genus Sphaeroides to the patient suffering from either neuropathic pain.
- One aspect of the present invention is a bird's nest yeast belonging to the genus Sphaeroides Swift for the production of any of pharmaceuticals, quasi drugs, health supplements, nutritional supplements, processed foods and soft drinks The use of fermented material.
- the present invention can provide an unknown material that is expected to have functionality while using a natural product as a raw material.
- FIG. 2 is a graph showing the content of essential amino acids contained in the fermentation broth according to Example 1.
- FIG. 3 is a graph showing the content of amino acids contained in the fermentation broth according to Example 1.
- FIG. 2 is a graph showing the content of vitamins contained in a fermentation broth according to Example 1.
- natural product refers to a substance produced by a living organism.
- Living organisms include animals, plants and microorganisms. The organism may be artificially bred. Substances produced by living organisms may be artificially obtained. Living things may be natural. A substance produced by an organism may be a natural product.
- the natural object refers to an object existing in the natural world, not an artificial object or an artificial object. That is, what is acquired from the natural world in the practice of the invention.
- the term “material” refers to a substance suitable for blending into a composition.
- the term “functional material” refers to a material that has, or is expected to have, some positive effects on the living body.
- the term “functional material” includes materials blended for the purpose of increasing the added value of these compositions.
- the functional material is preferably a substance produced from a natural product.
- the composition is preferably any one of a pharmaceutical, a quasi-drug, a health supplement, a nutritional supplement, a processed food, and a soft drink.
- pharmaceutical and “quasi-drug” include herbal medicine.
- health supplement include highly nutritive foods.
- the material is preferably a material added to the composition.
- the material is preferably a functional material.
- the material according to this embodiment is a fermented yeast nest of a bird's nest belonging to the genus Swift.
- birds belonging to the genus Swiftaceae may be referred to as the genus Swift.
- yeast fermented product represents a product in a state where the raw material is fermented in the presence of yeast.
- yeast includes, but is not limited to, for example, Saccharomyces cerevisiae.
- fermentation includes the degradation of raw materials by yeast, accompanied by anaerobic respiration of yeast.
- Yeast fermented material is a decomposition product of raw materials by yeast.
- the composition according to this embodiment is the above composition containing the above material.
- a composition is a life factor including symptoms associated with lifestyle-related diseases including diabetes, hypertension, cardiac ischemic disease and cerebral ischemic disease, symptoms associated with pathogen infection including viral infection and pathogenic microorganism infection, overwork and malnutrition. It may be used for at least one of prevention and amelioration of one or more symptoms selected from the group consisting of accompanying symptoms, memory impairment, and dryness of skin and accompanying wrinkle formation.
- composition may be administered to patients exhibiting the above symptoms. Administration may be oral.
- a nest of the genus Swallow is used as a raw material.
- yeast is added to the raw material, and the yeast is cultured together with the raw material.
- Suitable swallows include A. amelis (Acer alba swallow), A. brevirostris (Himalayan giant swallow), A. elaphra (Seychelles swallow), A. francica, A.I. fuchiphaga (Java swallow), A.I. germani (Malayana swallow), A. hirundinacea, A. et al. infuscata (Morkka swallow), A. inquieta (caroline swallow), A.I. leucophaeus (Tahitian swallow), A. maxima (a giant swallow), A.I. mearnsi (Philippine muziana swallow), A. nuditalsus (Papua yamaba swallow), A.
- the nest is a solid product of the genus Swallow.
- Secretions are sticky secretions. Secretions are secreted from the salivary glands of the genus Swallow.
- a nest of one species of the genus Swallow may be used as a raw material. Moreover, it is good also as a raw material combining the nest of two or more seeds. It is preferable to remove swallow excrement and waste products and other unnecessary materials from the nest.
- the material is obtained by adding yeast to the nest and fermenting the nest with yeast. It is preferable to add 10 to 100 g of yeast per 100 g of nest. Yeast may be artificially bred or may be obtained from nature.
- the above material is obtained as a fermentation broth for nests and yeast. Add more water to the raw material before fermentation. It is preferable to add water in order to add moisture. It is preferable to add 50 g to 10000 g of water with respect to 100 g of nest. It is preferable to ferment the raw material together with moisture. It is preferable to perform fermentation only with nests, yeast and water as raw materials.
- Yeast is added to the raw material nest and fermented for 24 hours or more and less than 3 years. Fermentation is performed in a sealed state. This encourages the yeast to breathe anaerobically. Fermentation can be stably performed by periodically removing the gas filled in the fermenter. It is preferred to evaporate at least a portion of the water after fermentation. It is preferable to concentrate the fermentation broth by evaporation.
- the component having at least one of antiseptic effect, longevity improving function, and stability maintaining action is added to the fermentation broth obtained as described above.
- a component one or more compounds selected from the group consisting of various esters of paraoxybenzoic acid, sodium dehydroacetate, potassium sorbate, sodium sorbate, sodium acetate and a pH adjuster are preferred.
- Such fermentation liquid or product liquid can be the above-mentioned material.
- Such a fermented liquid or produced liquid can be blended in a stable state into a composition typified by pharmaceuticals, quasi drugs, foods for health supplements, foods for nutritional supplements, processed foods and soft drinks.
- the above-mentioned raw material can be suitably used as a raw material for producing these compositions. You may add the above-mentioned component to these compositions.
- raw materials may be used as active ingredients.
- Pharmaceutical dosage forms are supported by suppositories, ointments, solutions, dispersions, emulsions, powders, pills, lozenges, tablets, lozenges, buccals, capsules, chewing gums, and filamentous substrates. Or a pharmaceutical preparation for inhalation.
- the active ingredient is mixed with one or more of a carrier, excipient, binder, disintegrant, dissolution improver, swelling agent, anti-caking agent, anti-adhesion agent and lubricant. May be.
- the active ingredients are solvents, solvents, extenders, tonicity agents, solubilizers, solubilizers, emulsifiers, suspending agents, dispersants, viscosity modifiers, thickeners and containers. You may mix with one or more among adsorption inhibitors.
- the pharmaceutical product may be coated with a coating agent. A coating-forming auxiliary may be used.
- sustained release agents for pharmaceuticals, sustained release agents, sustaining agents, immediate release agents, fast solubilizers, absorption enhancers, penetrants, gelling agents, coagulation accelerators, light stabilizers, preservatives, preservatives, moistureproof agents , Emulsifiers, suspending agents, dispersion stabilizers, anti-coloring agents, oxygen scavengers, antioxidants, flavoring agents, flavoring agents, coloring agents, pigments, paints, bleaching agents, foaming agents, antifoaming agents, skin irritation
- one or more of soothing agents, wetting agents, moisturizing agents, antistatic agents, buffering agents, pH adjusting agents, anti-isomerization agents, decomposition preventing agents, interaction preventing agents and side effect reducing agents may be added. Good.
- the administration route of the drug may be oral, injection, body cavity, mucous membrane, transdermal, or in vivo implantation.
- the shape of quasi-drugs, foods for health supplements and foods for nutritional supplements can be the same as the above-mentioned pharmaceutical products.
- Processed food may be, for example, jelly, gummi, candy, gum, snack confectionery, baked confectionery, retort food or instant food.
- the above materials include viscous substances mucin, N-acetylneuraminic acid, various types of cytokines, and compounds typified by sugar chains unique to swallow nests.
- Such a material can be suitably used as the functional material described above. This is because such a material has or is expected to have at least one of the effects of preventing and improving the above-mentioned symptoms.
- the viscous substance mucin is considered as the main component of mucus secreted from epithelial cells of animals.
- N-acetylneuraminic acid is a compound representing sialic acid which is a kind of carbohydrate.
- N-acetylneuraminic acid is sialic acid having the highest abundance ratio among sialic acids existing in nature. According to the description in JP-A-2008-189635, it has been confirmed that N-acetylneuraminic acid has an antiallodynic action and improves neuropathic pain.
- cytokines are cytokines represented by interleukin-6, epidermal growth factor (EGF) and fibroblast growth factor (FGF).
- interleukin-6 interleukin-6
- EGF epidermal growth factor
- FGF fibroblast growth factor
- the sugar chain has at least one of a function of reducing one or more symptoms associated with the lifestyle-related diseases and a function of preventing virus infection.
- the raw material is the nest formed by the genus Swallow, which is formed by sticking with the sticky secretions secreted from the salivary glands.
- the nest is A. amelis (Acer alba swallow), A. brevirostris (Himalayan giant swallow), A. elaphra (Seychelles swallow), A. francica, A.I. fuchiphaga (Java swallow), A.I. germani (Malayana swallow), A. hirundinacea, A. et al. infuscata (Morkka swallow), A. inquieta (caroline swallow), A.I. leucophaeus (Tahitian swallow), A. maxima (a giant swallow), A.I.
- the fermentation liquor is generated in the above process.
- a product liquid is obtained by adding a preservative and a pH stabilizer to the fermentation broth.
- the content of N-acetylneuraminic acid in the product liquid is 7% or more. Fermentation using only nests, yeast and water as raw materials contributes to realizing a suitable fermentation environment.
- N-acetylneuraminic acid has an antiallodynic action, that is, an improvement in neuropathic pain.
- the fermentation broth produced in a suitable fermentation environment contains 7% or more of N-acetylneuraminic acid. Therefore, the fermented liquid is expected to have an antiallodynic action.
- neuropathic pain can be expected by administering a suitable amount of fermentation broth or product to patients with allodynia or neuropathic pain.
- generation liquid is suitable for improvement of allodynia or neuropathic pain.
- the product solution contained an amino acid.
- Such amino acids contained nine essential amino acids.
- the product solution contained 18 kinds of amino acids including ⁇ -amino acid butyric acid in addition to 9 kinds of essential amino acids.
- the produced solution contained vitamins.
- the composition of such vitamins is characterized in that the proportion of vitamin C (ascorbic acid) and inositol in the vitamin B group was large.
- the concentrated liquid can be obtained by evaporating the moisture of the fermentation liquid obtained in Example 1 by heating.
- a product solution can be obtained by adding a preservative and a pH stabilizer to the concentrate.
- the concentrate obtained by the method of this example is also expected to have an antiallodynic action. For this reason, improvement of neuropathic pain can be expected by administering a suitable amount of concentrate or product to patients with allodynia or neuropathic pain. For this reason, the composition containing a concentrate or a production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (11)
- アマツバメ科アナツバメ属に属する鳥の巣の酵母発酵物。
- 医薬品、医薬部外品、健康補助用食品、栄養補助用食品、加工食品及び清涼飲料水のいずれかとしての使用のための、
請求項1に記載の酵母発酵物。 - アマツバメ科アナツバメ属に属する鳥の巣の酵母発酵物を含有する組成物。
- 医薬品、医薬部外品、健康補助用食品、栄養補助用食品、加工食品及び清涼飲料水のいずれかである、
請求項3に記載の組成物。 - アロディニア又は神経因性疼痛を改善するための、
請求項3に記載の組成物。 - 生活習慣病の予防及び改善のうち少なくとも一方のための、
請求項3に記載の組成物。 - 前記生活習慣病は糖尿病、高血圧症、心虚血疾患及び脳虚血疾患のうちの少なくともいずれか一つである、
請求項6に記載の組成物。 - ウイルス感染を防ぐための、
請求項3に記載の組成物。 - アマツバメ科アナツバメ属に属する鳥の巣を原料とし、
前記原料に酵母を添加し、
前記原料を前記酵母で発酵させる、
素材製造方法。 - 発酵前の前記原料にさらに水分を添加し、
前記原料を前記水分とともに発酵させ、
発酵は密閉状態で行う、
請求項9に記載の素材製造方法。 - 発酵後、前記水分の少なくとも一部を蒸発させる、
請求項10に記載の素材製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201705801VA SG11201705801VA (en) | 2015-02-03 | 2015-06-25 | Ingredient made from swiftlet nest as raw material, composition, and method for producing ingredient |
JP2016572943A JP6651466B2 (ja) | 2015-02-03 | 2015-06-25 | アナツバメ巣を原材料とする酵母発酵液、組成物及び素材の製造方法 |
CN201580074756.3A CN107405365B (zh) | 2015-02-03 | 2015-06-25 | 以金丝燕燕窝为原料制作的材料、组分及材料的制作方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015031065 | 2015-02-03 | ||
JP2015-031065 | 2015-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016125208A1 true WO2016125208A1 (ja) | 2016-08-11 |
Family
ID=56563575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/003205 WO2016125208A1 (ja) | 2015-02-03 | 2015-06-25 | アナツバメ巣を原材料とする素材、組成物及び素材の製造方法 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6651466B2 (ja) |
CN (1) | CN107405365B (ja) |
SG (1) | SG11201705801VA (ja) |
WO (1) | WO2016125208A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112931862A (zh) * | 2021-03-15 | 2021-06-11 | 北京市小仙炖电子商务有限公司 | 一种冰糖燕窝及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0242962A (ja) * | 1988-08-04 | 1990-02-13 | Susumu Murofushi | 機能性食品の製造方法 |
JP2002068988A (ja) * | 2000-08-23 | 2002-03-08 | Combi Corp | ウイルス感染抑制剤及びそれを含有する飲食品 |
JP2003259835A (ja) * | 2001-12-28 | 2003-09-16 | Oubiken:Kk | 発酵製品の製造とその利用 |
JP2003292444A (ja) * | 2002-02-04 | 2003-10-15 | Kyowa Hakko Kogyo Co Ltd | インスリン分泌促進剤 |
JP2005185241A (ja) * | 2003-12-26 | 2005-07-14 | Takashi Kondo | 発酵健康食品及びその製造方法 |
JP2005185242A (ja) * | 2003-12-26 | 2005-07-14 | Takashi Kondo | プラセンタを含有した健康食品及びその製造方法 |
JP2007061058A (ja) * | 2005-09-02 | 2007-03-15 | Hideo Yamamoto | 糖鎖栄養素を含む免疫強化食品及びその製造方法 |
JP2008189635A (ja) * | 2007-02-08 | 2008-08-21 | Nippon Zoki Pharmaceut Co Ltd | 疼痛疾患治療剤 |
JP2014159491A (ja) * | 2014-06-09 | 2014-09-04 | Combi Corp | コラーゲン産生低下抑制剤、それを含む皮膚外用組成物および化粧料 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05214003A (ja) * | 1992-02-04 | 1993-08-24 | Mect Corp | 好中球遊走阻止薬 |
JP4976629B2 (ja) * | 2001-09-27 | 2012-07-18 | コンビ株式会社 | 美肌促進剤 |
WO2009008362A1 (ja) * | 2007-07-12 | 2009-01-15 | Yotsuba Milk Products Co., Ltd. | シアル酸化合物含有組成物の製造方法 |
CN102334680B (zh) * | 2011-08-08 | 2012-12-19 | 邓毛程 | 一种红曲燕窝及其制备方法 |
CN102362637B (zh) * | 2011-09-30 | 2013-03-13 | 邓毛程 | 利用微生物活菌悬液和/或粗酶液去除燕窝中亚硝酸盐的方法与应用 |
CN104146885A (zh) * | 2014-07-14 | 2014-11-19 | 武汉中科光谷绿色生物技术有限公司 | N-乙酰神经氨酸水合物在育发产品中的应用 |
-
2015
- 2015-06-25 SG SG11201705801VA patent/SG11201705801VA/en unknown
- 2015-06-25 WO PCT/JP2015/003205 patent/WO2016125208A1/ja active Application Filing
- 2015-06-25 JP JP2016572943A patent/JP6651466B2/ja active Active
- 2015-06-25 CN CN201580074756.3A patent/CN107405365B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0242962A (ja) * | 1988-08-04 | 1990-02-13 | Susumu Murofushi | 機能性食品の製造方法 |
JP2002068988A (ja) * | 2000-08-23 | 2002-03-08 | Combi Corp | ウイルス感染抑制剤及びそれを含有する飲食品 |
JP2003259835A (ja) * | 2001-12-28 | 2003-09-16 | Oubiken:Kk | 発酵製品の製造とその利用 |
JP2003292444A (ja) * | 2002-02-04 | 2003-10-15 | Kyowa Hakko Kogyo Co Ltd | インスリン分泌促進剤 |
JP2005185241A (ja) * | 2003-12-26 | 2005-07-14 | Takashi Kondo | 発酵健康食品及びその製造方法 |
JP2005185242A (ja) * | 2003-12-26 | 2005-07-14 | Takashi Kondo | プラセンタを含有した健康食品及びその製造方法 |
JP2007061058A (ja) * | 2005-09-02 | 2007-03-15 | Hideo Yamamoto | 糖鎖栄養素を含む免疫強化食品及びその製造方法 |
JP2008189635A (ja) * | 2007-02-08 | 2008-08-21 | Nippon Zoki Pharmaceut Co Ltd | 疼痛疾患治療剤 |
JP2014159491A (ja) * | 2014-06-09 | 2014-09-04 | Combi Corp | コラーゲン産生低下抑制剤、それを含む皮膚外用組成物および化粧料 |
Also Published As
Publication number | Publication date |
---|---|
CN107405365B (zh) | 2021-06-01 |
JP6651466B2 (ja) | 2020-02-19 |
SG11201705801VA (en) | 2017-08-30 |
JPWO2016125208A1 (ja) | 2017-11-16 |
CN107405365A (zh) | 2017-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2526199C2 (ru) | Композиция, способствующая выработке коллагена | |
EP2931289B1 (fr) | Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses | |
US8962684B2 (en) | Antioxidant composition | |
WO2016125208A1 (ja) | アナツバメ巣を原材料とする素材、組成物及び素材の製造方法 | |
EA009677B1 (ru) | Средство для лечения гипергликемии и его применение | |
JP2006075084A (ja) | セロリから得られる発酵物 | |
KR20180122380A (ko) | 피칼리박테리움속 세균증식제 | |
JP4000946B2 (ja) | 冬虫夏草の新規製造方法及び得られた冬虫夏草とその使用 | |
JP2006075083A (ja) | ゴーヤから得られる発酵物 | |
WO2018207741A1 (ja) | PGC-1α生合成促進剤および遅筋速筋化抑制剤 | |
US20220218772A1 (en) | Mushroom blend for increasing butyrate production in the gut biome | |
JP2009269832A (ja) | カルシトニン遺伝子関連ペプチド及びインスリン様成長因子−1の産生促進組成物 | |
JP2014031323A (ja) | セラミド産生促進用組成物 | |
US10925304B2 (en) | Method for treating chronic fatigue syndrome, idiopathic chronic fatigue, and fibromyalgia | |
JP2022115770A (ja) | 低温発酵減圧抽出法 | |
JP7104193B2 (ja) | 筋肉増強剤 | |
JP2006075085A (ja) | パセリから得られる発酵物 | |
JP2004292355A (ja) | 抗ストレス剤 | |
KR101184365B1 (ko) | 코디셉스 밀리타리스 kctc 11455 bp로 발효시킨 녹용을 유효성분으로 포함하는 항산화 및 성장촉진용 조성물 및 그 제조방법 | |
KR20220115748A (ko) | 신규한 엔테로코커스 패칼리스 균주 및 이의 유청 발효물을 포함하는 구강질환 또는 대장질환의 예방 또는 개선용 식품 조성물 | |
CN104523736B (zh) | 一种防治心肌梗死的药物组合物及其应用 | |
CN118240722A (zh) | 一种副干酪乳酪杆菌及其防治牙周炎的应用 | |
JP2020079309A (ja) | 筋肉増強剤 | |
ES2957341A1 (es) | Cepa de hericium erinaceus y su uso en enfermedades neurodegenerativas, cancer y enfermedades digestivas | |
KR20220115758A (ko) | 신규한 엔테로코커스 패칼리스 균주 및 락토코커스 락티스 균주, 및 이의 유청 발효물을 포함하는 구강질환 또는 대장질환의 예방 또는 개선용 식품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15881025 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016572943 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201705801V Country of ref document: SG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15881025 Country of ref document: EP Kind code of ref document: A1 |